ABBV-744 CANCER TREATMENT CLINICAL TRIALS - AN OVERVIEW

In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will receive treatment till sickness progression or even the members are unable to tolerate the study drugs.There might be larger treatment stress for individuals in this trial as compared to their common of